349 related articles for article (PubMed ID: 24474430)
41. Risk factors and scoring system for predicting bacterial resistance to cefepime as used empirically in haematology wards.
El Maaroufi H; Goubard A; Redjoul R; Legrand P; Pautas C; Mikdame M; Doghmi K; Toma A; Maury S; Schwarzinger M; Cordonnier C
Biomed Res Int; 2015; 2015():945769. PubMed ID: 26075276
[TBL] [Abstract][Full Text] [Related]
42. Different impact of the appropriateness of empirical antibiotics for bacteremia among younger adults and the elderly in the ED.
Lee CC; Chang CM; Hong MY; Hsu HC; Ko WC
Am J Emerg Med; 2013 Feb; 31(2):282-90. PubMed ID: 23000336
[TBL] [Abstract][Full Text] [Related]
43. Gram-negative bacteraemia in non-ICU patients: factors associated with inadequate antibiotic therapy and impact on outcomes.
Marschall J; Agniel D; Fraser VJ; Doherty J; Warren DK
J Antimicrob Chemother; 2008 Jun; 61(6):1376-83. PubMed ID: 18344548
[TBL] [Abstract][Full Text] [Related]
44. Quantifying the importance of active antimicrobial therapy among patients with Gram-negative bloodstream infections: Cefepime as a representative agent.
Miglis C; Rhodes NJ; Liu J; Gener J; Hang E; Scheetz MH
Int J Antimicrob Agents; 2019 Jan; 53(1):95-97. PubMed ID: 30315921
[TBL] [Abstract][Full Text] [Related]
45. Nosocomial Gram-negative bacteremia in intensive care: epidemiology, antimicrobial susceptibilities, and outcomes.
Sligl WI; Dragan T; Smith SW
Int J Infect Dis; 2015 Aug; 37():129-34. PubMed ID: 26159847
[TBL] [Abstract][Full Text] [Related]
46. Bacteremia in patients with hematological malignancies.
Wang FD; Lin ML; Liu CY
Chemotherapy; 2005 May; 51(2-3):147-53. PubMed ID: 15886475
[TBL] [Abstract][Full Text] [Related]
47. Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study.
Su TY; Ye JJ; Yang CC; Huang CT; Chia JH; Lee MH
Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):52. PubMed ID: 28738848
[TBL] [Abstract][Full Text] [Related]
48. Stratification of the impact of inappropriate empirical antimicrobial therapy for Gram-negative bloodstream infections by predicted prognosis.
Cain SE; Kohn J; Bookstaver PB; Albrecht H; Al-Hasan MN
Antimicrob Agents Chemother; 2015 Jan; 59(1):245-50. PubMed ID: 25348527
[TBL] [Abstract][Full Text] [Related]
49. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis.
Safdar N; Handelsman J; Maki DG
Lancet Infect Dis; 2004 Aug; 4(8):519-27. PubMed ID: 15288826
[TBL] [Abstract][Full Text] [Related]
50. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis.
Micek ST; Welch EC; Khan J; Pervez M; Doherty JA; Reichley RM; Kollef MH
Antimicrob Agents Chemother; 2010 May; 54(5):1742-8. PubMed ID: 20160050
[TBL] [Abstract][Full Text] [Related]
51. [Nosocomial bloodstream infections caused by gram-negative bacilli: epidemiology and risk factors for mortality].
Lizaso D; Aguilera C K; Correa M; Yantorno ML; Cuitiño M; Pérez L; Lares M; Parra Gde L; Esposto A
Rev Chilena Infectol; 2008 Oct; 25(5):368-73. PubMed ID: 18949150
[TBL] [Abstract][Full Text] [Related]
52. A propensity score analysis shows that empirical treatment with linezolid does not increase the thirty-day mortality rate in patients with Gram-negative bacteremia.
Ternavasio-de la Vega HG; Mateos-Díaz AM; Martinez JA; Almela M; Cobos-Trigueros N; Morata L; De-la-Calle C; Sala M; Mensa J; Marcos M; Soriano A
Antimicrob Agents Chemother; 2014 Dec; 58(12):7025-31. PubMed ID: 25199780
[TBL] [Abstract][Full Text] [Related]
53. Loading dose plus continuous/extended infusion versus intermittent bolus of β-lactams for the treatment of Gram-negative bacteria bloodstream infections: a propensity score-adjusted retrospective cohort study.
Bavaro DF; Belati A; Diella L; Frallonardo L; Guido G; Papagni R; Pellegrino C; Brindicci G; De Gennaro N; Di Gennaro F; Denicolò S; Ronga L; Mosca A; Pomarico F; Dell'Aera M; Stufano M; Dalfino L; Grasso S; Saracino A
J Antimicrob Chemother; 2023 Sep; 78(9):2175-2184. PubMed ID: 37428015
[TBL] [Abstract][Full Text] [Related]
54. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia.
Vicari G; Bauer SR; Neuner EA; Lam SW
Clin Infect Dis; 2013 Feb; 56(3):398-404. PubMed ID: 23090926
[TBL] [Abstract][Full Text] [Related]
55. Predictive scoring model of mortality in Gram-negative bloodstream infection.
Al-Hasan MN; Lahr BD; Eckel-Passow JE; Baddour LM
Clin Microbiol Infect; 2013 Oct; 19(10):948-54. PubMed ID: 23190091
[TBL] [Abstract][Full Text] [Related]
56. Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug?
Vardakas KZ; Rafailidis PI; Konstantelias AA; Falagas ME
J Infect; 2013 May; 66(5):401-14. PubMed ID: 23142195
[TBL] [Abstract][Full Text] [Related]
57. Effect of elevated imipenem/cilastatin minimum inhibitory concentrations on patient outcomes in Gram-negative bloodstream infections.
McLaughlin MM; Miglis C; Skoglund E; Wagner J; Advincula MR; Scheetz MH
J Glob Antimicrob Resist; 2018 Jun; 13():261-263. PubMed ID: 29432939
[TBL] [Abstract][Full Text] [Related]
58. Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.
Pajot O; Burdet C; Couffignal C; Massias L; Armand-Lefevre L; Foucrier A; Da Silva D; Lasocki S; Laouénan C; Mentec H; Mentré F; Wolff M
J Antimicrob Chemother; 2015 May; 70(5):1487-94. PubMed ID: 25630642
[TBL] [Abstract][Full Text] [Related]
59. Risk Factors and Outcomes for Ineffective Empiric Treatment of Sepsis Caused by Gram-Negative Pathogens: Stratification by Onset of Infection.
Micek ST; Hampton N; Kollef M
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109168
[TBL] [Abstract][Full Text] [Related]
60. Empiric combination therapy for gram-negative bacteremia.
Sick AC; Tschudin-Sutter S; Turnbull AE; Weissman SJ; Tamma PD
Pediatrics; 2014 May; 133(5):e1148-55. PubMed ID: 24709936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
